Aptevo Therapeutics Inc (NASDAQ:APVO)
| 0.1899 Delayed Data As of Dec 01 |  +0.0029 / +1.55%Today’s Change | 0.15 Today|||52-Week Range 7.20 | -91.81% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $3.3M |
Company Description
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.
Contact Information
Aptevo Therapeutics, Inc. 2401 4th Avenue Seattle Washington 98121 |
Employees
Shareholders
| Individual stakeholders | 61.90% |
| Other institutional | 27.64% |
| Mutual fund holders | 2.06% |
Top Executives
| Marvin L. White | President, Chief Executive Officer & Director |
| Jeffrey G. Lamothe | Chief Operating Officer & Executive Vice President |
| Daphne L. Taylor | Chief Financial Officer & Senior Vice President |
| Dirk Huebner | Chief Medical Officer |
| Miriam Weber Miller | Investor Relations Contact |
